ProMetic’s Experimental IPF Therapy PBI-4050 Demonstrates Anti-Fibrotic Properties in Human Cells
ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary fibrosis. Two presentations at the 2015 European Renal Association Annual Meeting identified that PBI-4050 reduces fibrosis in human cells. “Our data correlates the regulation activity of PBI-4050 on key fibrotic…